Convergence at the Molecular Level
A new study published in Science has uncovered one of the most striking examples of convergent evolution ever documented at the molecular level. Researchers found that multiple unrelated animal species have independently evolved defensive toxins that mimic bradykinin, a peptide that plays a central role in the human pain and inflammation response. The convergence is so precise that these independently evolved toxins interact with the same human receptors through nearly identical molecular mechanisms, despite emerging from completely different evolutionary lineages.
Bradykinin is a naturally occurring peptide in mammals that dilates blood vessels, increases vascular permeability, and triggers pain signaling. It is released during tissue injury as part of the body's inflammatory response. The discovery that diverse venomous and toxic animals have independently stumbled upon molecular mimics of this specific peptide suggests that bradykinin represents a particularly effective molecular target for defensive weapons — so effective that evolution has converged on it again and again.
The Species Involved
The study analyzed toxins from a range of taxonomically distant species, including certain venomous snakes, frogs, insects, and marine organisms. In each case, the defensive secretions contained peptides that were structurally distinct from each other in their amino acid sequences but functionally equivalent in their ability to bind to and activate bradykinin receptors in mammalian tissue. This functional convergence despite structural divergence is the hallmark of independent evolutionary invention rather than shared ancestry.
The research team used advanced protein structure prediction tools to model the three-dimensional shapes of these toxin peptides and compare their receptor-binding surfaces. Despite having different evolutionary origins and different overall shapes, the toxins shared critical binding features at the molecular interface where they contact the bradykinin receptor. This convergence at the binding interface, rather than across the entire molecule, demonstrates that evolution found multiple structural solutions to the same functional problem.
Why Bradykinin?
The researchers propose that bradykinin's central role in the mammalian pain response makes it an unusually attractive target for defensive toxins. An animal that can inject a substance mimicking bradykinin into a predator triggers immediate, intense pain that discourages the predator from continuing its attack. Unlike toxins that kill predators, which provide no survival benefit to an individual animal that has already been eaten, pain-inducing toxins encourage the predator to release its prey while the prey is still alive.
This defensive logic explains why bradykinin mimicry has evolved preferentially over mimicry of other mammalian signaling peptides. Pain is one of the fastest and most compelling signals a predator can experience, and the bradykinin pathway activates within seconds of receptor binding. A defensive toxin that requires minutes or hours to take effect is far less useful than one that causes immediate, sharp pain at the moment of contact.
Implications for Drug Development
The discovery has practical implications beyond evolutionary biology. The bradykinin pathway is already a target for pharmaceutical research, particularly in the treatment of hereditary angioedema, a condition caused by overactive bradykinin signaling, and in the development of pain management therapies. The diverse collection of naturally evolved bradykinin mimics identified in the study represents a library of molecular structures that drug developers can investigate as potential therapeutic agents or as templates for designing synthetic bradykinin receptor modulators.
Each independently evolved mimic provides a different structural approach to activating the same receptor, and some of these structures may have pharmacological properties — such as selective receptor subtype binding, altered duration of action, or improved stability — that natural bradykinin lacks. The study effectively provides pharmaceutical researchers with a set of evolutionary experiments that have already been conducted over millions of years, each yielding a potentially useful molecular scaffold.
A Window Into Evolutionary Constraints
For evolutionary biologists, the study provides powerful evidence that the space of possible molecular solutions to biological problems is more constrained than previously appreciated. When the same molecular strategy evolves independently in distantly related organisms, it suggests that the laws of biochemistry and the structure of biological receptors create convergent selection pressures that channel evolution toward a limited set of optimal solutions. This principle, known as evolutionary constraint, implies that life on other planets facing similar biochemical challenges might converge on similar molecular solutions — a finding with implications that extend well beyond toxicology into astrobiology and the fundamental principles governing the evolution of biological systems.
This article is based on reporting by Science (AAAS). Read the original article.
